Ironwood submits IW-2143 IND application to FDA

The trial will further evaluate pharmacokinetic profile of the anti-anxiety drug candidate in healthy volunteers.

Bionomics CEO and managing director Dr Deborah Rathjen said, "Ironwood has a strong team that has developed a thorough clinical development program for IW-2143."

Data from preclinical studies suggest that IW-2143 exhibits anti-anxiety activity and encourages neurite outgrowth under lab conditions.

Healthy volunteers who took part in a two arm phase I study did not demonstrate impaired attention after receiving IW-2143.

Electroencephalography (EEG) data collected from IW-2143 dosed subjects confirmed the pharmacodynamic effect.